Sattva S. Neelapu, M.D.

Professional Educational Materials

1. Neelapu SS, al E. IEC Therapy Toxicity Assessment and Management (CARTOX). MD Anderson Cancer Center, 2017.
2. Neelapu SS, al E. CARTOX App. MD Anderson Cancer Center.

Abstracts

1. Lionel A, Kui N, Sun R, Aboismail E, Tewari SO, Zaki AA, Gouni S, Jain P, Chihara D, Iyer SP, Wang M, Nair R, Malpica Castillo LE, Lee HJ, Nze C, Fayad LE, Hagemeister F, Rodriguez MA, Ayers AA, Gutierrez C, Rondon G, Khawaja F, Kebriaei P, Shpall EJ, Flowers CR, Westin JR, Strati P, WANG W, Wang SA, Ahmed S, Neelapu SS. Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma. ASH - American Society of Hematology, 2024. e-Pub 2024.
2. Zaki AA, Sutton M, Rehman A, Le CC, Gammon S, Napoli A, Yang P, Saini NY, Ahmed S, Issa GC, Kebriaei P, Davies M, Shpall EJ, Varghese J, Flynt L, Neelapu SS, Piwnica-Worms D. Imaging Activated Innate Immune Myeloid Cells in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy. ASH - American Society of Hematology, 2024. e-Pub 2024.
3. Patel KK, Manasanch EE, Lee HC, Ye J, Thomas SK, Weber DM, Becnel MR, Gaballa MR, Bansal H, Berkova Z, Neelapu SS, Haymaker CL, Dang M, Wang L, Lizee G, Orlowski RZ. Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM). ASH - American Society of Hemtology, 2024. e-Pub 2024.
4. Jain H, Karulkar A, Jaiswal AK, Kalra D, Ravikumar S, Shah S, Firfiray A, Pendhari J, Sharma N, Shetty A, Nayak L, Bagal B, Banavali S, Narula G, Melinkeri SR, Aribandi A, Agrawal N, Wilson L, Desai P, Navkudkar A, Tembhare P, Khattry N, Sridhar E, Patkar N, Shet T, Sakhadeo U, Subramanian PG, Thorat J, Ghosh K, Agrawal A, Jain Y, Rangarajan V, Bhosle S, Laskar S, Kakoti S, Shetty N, Patil V, Baheti A, Biswas S, Salunkhe G, Gala K, Purwar S, Sengar M, Shah NN, Neelapu SS, Purwar R. Talicabtagene Autoleucel (humanized CD19 CAR-T) As a Second Line Therapy in r/r B-Cell Lymphoma: Sub-Analysis from a Phase I/II Trial. ASH - American Society of Hematology, 2024. e-Pub 2024.
5. Nair R, Duenas DE, Liu J, Prakash R, Zhou C, Koksoy AA, Xu J, McAllen SA, Malpica L, Luthra R, Vega F, Miranda RN, Zhang J, Medeiros L, Haymaker CL, Flowers CR, Neelapu SS, Iyer SP. An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL. ASH - American Society of Hematology, 2024. e-Pub 2024.
6. Gonugunta AS, Prakash R, Nair R, Zaki AA, Ahmed S, Nze C, Chihara D, Hagemeister F, Lee HJ, Westin JR, Patel KK, Fayad LE, Malpica L, Rodriguez MA, Wang M, Jain P, Strati P, Neelapu SS, Flowers CR, Iyer SP. T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center. ASH - American Society of Hematology, 2024. e-Pub 2024.
7. Wang XS, Srour SA, Neelapu SS, Shen S, Noor L, Ahmed S, Shpall EJ. Developing a Fit-for-Purpose Composite Symptom Score for Representing Symptom Burden for Managing CRS and Icans after CAR T-Cell Therapy. ASH - American Society of Hematology, 2024. e-Pub 2024.
8. Fang PQ, Wu SY, Gunther JR, Frank A, Zemskiy P, Zaitsev A, Bolshakov ES, Terenteva A, Nomie K, Abreu M, Ow K, Santiago M, Varghese J, Ayers A, Henderson J, Ahmed S, Westin JR, Flowers CR, Neelapu SS, Dabaja BS, Pinnix CC, Strati P. Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy. ASH - American Society of Hematology, 2024. e-Pub 2024.
9. Jallouk AP, Ge Z, Kaimal V, Robbins PB, Roberts ZJ, Neelapu SS, Bachireddy P. Clinical Response after Allogeneic CAR T Cell Therapy Is Linked to Expansion of Identical CD8+ Effector-like T Cell Clones. ASH - American Society of Hematology, 2024. e-Pub 2024.
10. Hammond D, Sasaki K, Takahashi K, Shpall EJ, Popat U, Oran B, Al-Atrash G, Patel KK, Westin JR, Neelapu SS, Alvarado-Valero Y, Chien KS, Daver N, Montalban-Bravo G, Maiti A, Yilmaz M, Jabbour E, Pemmaraju N, Swaminathan M, Ishizawa J, Jain N, Ferrajoli A, Ravandi F, Kornblau SM, Borthakur G, Garcia-Manero G, Kantarjian HM, Reville PK, Abbas HA. Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies. ASH - American Society of Hematology, 2024. e-Pub 2024.
11. Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, Vos SD, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt JD, Wulff J, Shen R, Zhang W, Poddar S, Miao H, Nikolajeva O, Jacobson CA. 5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. ASH - American Society of Hematology, 2024. e-Pub 2024.
12. Poddar S, Yan J, Tiwari G, Rinchai D, Zhang W, Budka J, Peng W, Salunkhe S, Davis M, Song Q, Beygi S, Miao H, Mattie M, Shen R, Jacobson CA, Bedognetti D, Filosto S, Neelapu SS. Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel. ASH - American Society of Hematology, 2024. e-Pub 2024.
13. Lionel A, Gouni S, Feng L, Gaulin C, Gonugunta AS, Saridogan T, Abreu M, Varghese J, Ow K, Santiago M, Zaki AA, Adkins S, Ayers AA, Hawkins M, Kebriaei P, Shpall EJ, Iyer SP, Jain P, Wang M, Flowers CR, Ramdial J, Nastoupil L, Westin JR, Strati P, Neelapu SS, Chatterjee D, Ahmed S. Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma. ASH - American Society of Hematology, 2024. e-Pub 2024.
14. Saul EE, Valcarcel B, Ayers AA, Noorani M, Chihara D, Furqan F, Ahmed S, Iyer SP, Neelapu SS, Fayad LE, Hagemeister F, Nze C, Jain P, Wang M, Strati P, Chauhan A, Vega F, Flowers CR, Westin JR. Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma. ASH - American Society of Hematology, 2024. e-Pub 2024.
15. Gouni S, Lionel A, Feng L, Gaulin C, Reddy T, Gonugunta AS, Chu V, Hopper T, Ayers AA, Jackson I, Zaki AA, Hildebrandt MA, Nastoupil L, Chihara D, Nze C, Ramdial J, Shpall EJ, Westin JR, Flowers CR, Strati P, Neelapu SS, Lynn R, Ahmed S. Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma. ASH - American Society of Hematolgoy, 2024. e-Pub 2024.
16. Zhuang TZ, Feng L, Chihara D, Nze C, Ayers AA, Noorani M, Ayres JD, Duenas DE, Balakrishnan K, Nesterenko E, Meerson M, Zornikova K, Nomie K, Kotlov N, Fowler N, Rodriguez MA, Neelapu SS, Flowers CR, Strati P. Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma. ASH - American Society of Hematology, 2024. e-Pub 2024.
17. Jain H, Karulkar A, Kalra D, Ravikumar S, Shah S, Firfiray A, Pendhari J, Manivasagam S, Vaibhaw A, Saroha A, Jaiswal AK, Shetty A, Nayak L, Bagal B, Siddharthan N, Kaul E, Mehta P, Gupta A, Khattry N, Jindal N, Shah SP, Boya RK, Boyella PK, Desai P, Navkudkar A, Purwar S, Sengar M, Shah NN, Neelapu SS, Purwar R. Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile. ASH - American Society of Hematology, 2024. e-Pub 2024.
18. Kim K, Ayers A, Ahmed S, Claret L, Strati P, Nair R, Nze C, Ramdial J, Torres J, Shpall EJ, Fayad LE, Nastoupil L, Westin JR, Flowers CR, Neelapu SS, Chihara D. Identifying the Barriers of Clinical Trial Access after CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma. ASH - American Society of Hematology, 2024. e-Pub 2024.
19. Kim K, Chihara D, Fayad LE, Neelapu SS, Ahmed S, Hagemeister F, Nze C, Iyer SP, Jain P, Wang M, Strati P, Furqan F, Chauhan A, Green MR, Flowers CR, Westin JR. Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma. ASH - American Society of Hematology, 2024. e-Pub 2024.
20. Szymura S, Cha S, Wang L, Zhang T, Dong Z, Anderson A, Oh E, Wang Z, Lee V, Parshottham S, Rao S, Olsem JB, Crumpton BN, Lee HC, Manasanch EE, Neelapu SS, Thomas SK, Kwak LW. Early Intervention and Favorable Biologic Effects of Personalized Neoantigen Vaccines on the Tumor Immune Microenvironment in Smoldering Waldenstrom Macroglobulinemia. ASH - American Society of Hematology, 2023. e-Pub 2023.
21. Mattie M, Grosso M, Auguste A, Arnaud D, Locke FL, Neelapu SS, Miklos DB, Jacobson CA, Lekakis LJ, Lin Y, Ghobadi A, Kim JJ, Nater J, Shen RR, Galon J. Pre- and Post-Treatment Immune Contexture Correlates with Long Term Response in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel (axi-cel). ASH - American Society of Hematology, 2023. e-Pub 2023.
22. Szymura S, Cha S, Wang L, Zhang T, Dong Z, Anderson A, Oh E, Wang Z, Lee V, Parshottham S, Rao S, Olsem JB, Crumpton BN, Lee H, Manasanch EE, Neelapu SS, Thomas SK, Kwak LW. Early Intervention and Favorable Biologic Effects of Personalized Neoantigen Vaccines on the Tumor Immune Microenvironment in Smoldering Waldenstrom Macroglobulinemia. ASH - American Society of Hematology, 2023. e-Pub 2023.
23. Spiegel JY, Jain MD, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, Lekakis LJ, Reagan PM, Oluwole OO, McGuirk JP, Deol A, Dorritie K, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz JL, Ulrickson ML, Westin J, Chavez JC, Patel DA, Jacobs MT, Bansal R, Bennani N, Patel V, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Lunning MA, Dahiya S. Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium. ASH - American Society of Hematology, 2023. e-Pub 2023.
24. Chavez JC, Dickinson M, Munoz JL, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre NK, Vos SD, Lui C, Wulff J, Williams CM, Peng W, Kloos I, Xu H, Neelapu SS. 3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)Clinically Relevant Abstract. ASH - American Society of Hematology, 2023. e-Pub 2023.
25. Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson ML, Bachy E, Munshi PN, Casulo C, Maloney DG, Vos SD, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt JD, Peng W, Lui C, Wulff J, Shen RR, Poddar S, Lee A, Miao H, Nikolajeva O, Jacobson CA. Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial. ASH - American Society of Hematology, 2023. e-Pub 2023.
26. Westin J, Nair R, Fayad L, Iyer SP, Malpica L, Neelapu SS, Samaniego F, Steiner RE, Strati P, Mathew S, Griffith D, Nastoupil LJ, Montinez W, Rodriguez MA, Hagemeister F, Feng L, Vega F, Flowers CR, Ahmed S. Nivolumab and Ibrutinib for Treatment of Patients with Refractory or Relapsed Central Nervous System Lymphoma. ASH - American Society of Hematology, 2023. e-Pub 2023.
27. Karulkar A, Jaiswal AK, Khan A, Kalra D, Ravikumar S, Ghandade N, Patil R, Shah S, Firfiray A, Pendhari J, Patil R, Manivasagam S, Thorat J, Sharma N, Shetty A, Eipe T, Nayak L, Bagal B, Sengar M, Narula G, Shah NN, Neelapu SS, Jain H, Purwar R. Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility. ASH - American Society of Hematology, 2023. e-Pub 2023.
28. Elias A, Marques-Piubelli ML, Nair R, Prakash R, Ahmed S, Malpica L, Lee HJ, Xu J, Flowers CR, Neelapu SS, Vega F, Miranda R, Iyer SP. Prognostic Significance of CD30 Expression and Response to Brentuximab Vedotin in Patients with Angioimmunoblastic T Cell Lymphoma. ASH - American Society of Hematology, 2023. e-Pub 2023.
29. Strati P, Brandt A, Henderson J, Westin J, Nastoupil LJ, Zaki AA, Jallouk AP, Adkins S, Shpall EJ, Kebriaei P, Ramdial J, Saini NY, Ahmed S, Flowers CR, Neelapu SS, Hildebrandt M. Germline Determinants of Toxicity and Efficacy in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 Autologous CAR T-Cell Therapy. ASH - American Society of Hematology, 2023. e-Pub 2023.
30. Locke FL, Munoz JL, Tees MT, Lekakis LJ, Eradat HA, Vos SD, Nath R, Stevens DA, Malik SA, Shouse GP, Hamadani M, Oluwole OO, Perales M, Miklos DB, Nguyen A, Feng A, Navale L, Murray E, Kaufman GP, Kai K, Le Gall JB, Neelapu SS. ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas. ASH - American Society of Hematology, 2023. e-Pub 2023.
31. Gribben JG, Ghione P, Palomba ML, Ray MD, Limbrick-Oldfield EH, Kanters S, Bobillo S, Ribiero MT, Jacobson CA, Neelapu SS, Ghesquieres H, Nikolajeva O, Yan J, Wang H, Patel AR. An Updated Comparison of Clinical Outcomes from 4-Year Follow-up of Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma. ASH - American Society of Hematology, 2023. e-Pub 2023.
32. McCurry D, Westin J, Feng L, Ahmed S, Nair R, Steiner RE, Wynn L, Thomas J, Dsouza LH, Samaniego F, Neelapu SS, Nastoupil LJ. Phase 1 Dose Escalation Study of Pembrolizumab in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Large B-Cell or Follicular Lymphoma Following Progression after Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. ASH - American Society of Hematology, 2023. e-Pub 2023.
33. Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Spooner C, Kim JJ, Miao H, Xue AX, Zheng Y, Locke FL. Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1. ASH - American Society of Hematology, 2023. e-Pub 2023.
34. Jain H, Karulkar A, Kalra D, Ravikumar S, Ghandade N, Patil R, Shah S, Firfiray A, Pendhari J, Patil R, Manivasagam S, Sharma N, Shetty A, Nayak L, Bagal B, Banavali S, Narula G, Desai P, Navkudkar A, Tembhare P, Khattry N, Sridhar E, Patkar N, Gujral S, Shet T, Sakhadeo U, Subramanian PG, Thorat J, Prashant A, Punatar S, Gokarn A, Ghosh K, Agrawal A, Jain Y, Rangarajan V, Ojha S, Bhosle S, Laskar S, Kakoti S, Mirgh S, Hiregoudar S, Poojary M, Shetty N, Patil V, Baheti A, Biswas S, Salunkhe G, Gala K, Sengar M, Shah NN, Neelapu SS, Purwar R. High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial. ASH - American Society of Hematology, 2023. e-Pub 2023.
35. Ebinama U, Prakash R, Strati P, Ahmed S, Adkins S, Srour SA, Wang ML, Jain P, Shpall EJ, Lionel A, Lui M, Neelapu SS, Patel KK, Iyer SP. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS): A Review of Pharmacovigilance. ASH - American Society of Hematology, 2023. e-Pub 2023.
36. Jallouk AP, Ge Z, Kaimal V, Furmanak T, Sommer C, Lauron EJ, Sasu BJ, Neelapu SS, Bachireddy P. Cellular Mechanisms Affecting Allogeneic CAR T Cell Expansion and Rejection in Large B-Cell Lymphoma. ASH - American Society of Hematology, 2023. e-Pub 2023.
37. Westin J, Steiner RE, Chihara D, Ahmed S, Jain P, Malpica L, Iyer SP, Fayad L, Nair R, Nastoupil LJ, Neelapu SS, Henderson J, Rodriguez MA, Hagemeister F, Vega F, Pulsifer B, Tom J, Durmic I, Masand G, Feng L, Green MR, Flowers CR, Strati P. Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma. ASH - American Society of Hematology, 2023. e-Pub 2023.
38. Strati P, Feng L, Westin J, Nair R, Fayad L, Rodriguez MA, Chihara D, Malpica L, Henderson J, Gallardo M, Marques-Piubelli ML, Turova P, Zaitsev A, Wang I, Flowers CR, Nastoupil LJ, Neelapu SS. Addition of Acalabrutinib to Lenalidomide and Rituximab Induces High Complete Response Rates in Patients with Previously Untreated Follicular Lymphoma: Results of a Phase II Study. ASH - American Society of Hematology, 2023. e-Pub 2023.
39. Zaki AA, Feng L, Westin J, Nair R, Fayad L, Watson G, Adkins S, Shpall EJ, Marques-Piubelli ML, Henderson J, Nastoupil LJ, Flowers CR, Ahmed S, Neelapu SS, Strati P. A Phase II Study of Loncastuximab Tesirine As Consolidation Strategy in Patients with LBCL in PR at Day 30 after CAR T-Cell Therapy. ASH - American Society of Hematology, 2023. e-Pub 2023.
40. Bachy E, Neelapu SS, Chavez JC, Yakoub-Agha I, Lui C, Wulff J, Miao H, Nikolajeva O, Best T, Linot C, Jacobson CA. A Retrospective Intra-Patient Analysis from ZUMA-5: Axicabtagene Ciloleucel (Axi-Cel) Compared with Prior Standard-of-Care Therapy in Patients with Relapsed/Refractory Follicular Lymphoma. ASH - American Society of Hematology, 2023. e-Pub 2023.
41. Gunther J, Xu J, Bhutani MS, Strati P, Fang P, Wu S, Dabaja BS, Dong W, Bhosale P, Flowers CR, Nair R, Malpica L, Jain P, Neelapu SS, Rodriguez MA, Chihara D, Nastoupil LJ, Pinnix CC. Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Gastric MALT Lymphoma. ASH - American Society of Hematology, 2023. e-Pub 2023.
42. Locke FL, Lekakis LJ, Eradat H, Munoz J, Tees MT, de Vos S, Nath R, Stevens DA, Malik S, Popplewell L, Hamadani M, Oluwole OO, M-A P, Miklos DB, Fisher P, Goyal L, Kaufman G, Kai K, Balakumaran A, Neelapu SS. Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL). ASCO - Journal of Clinical Oncology 41(Suppl 16), 2023. e-Pub 2023.
43. Manasanch EE, Korde N, Lee HC, Patel K, Becnel M, Berrios D, Thomas SK, Iyer SP, Mailankody S, Amini B, Lin P, Berkova Z, Weber DM, Feng L, Neelapu SS, Jagannath S, Hildebrandt MAT, Orlowski RZ, Landgren O. ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM). ASCO - Journal of Clinical Oncology 41(Suppl 16), 2023. e-Pub 2023.
44. Ghione P, Palomba ML, Ray MD, Limbrick-Oldfield EH, Owen J, Kanters S, Bobillo S, Ribeiro MT, Jacobson CA, Neelapu SS, Ghesquieres H, Nahas M, Beygi S, Patel AR, Gribben JG. A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL). American Society of Hematology - Blood 140(Suppl 1):4676-4677, 2022. e-Pub 2022.
45. Steiner RE, Strati P, Flowers C, Neelapu SS, Green MR, Nastoupil LJ, Hagemeister FB, Feng L, Ahmed S, Nair R, Fayad L, Lee HJ, Rodriguez MA, Westin J. Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma. ASCO - Journal of Clinical Oncology 40(Suppl 16), 2022. e-Pub 2022.
46. Zhang T, Wang Z, S-C C, Anderson A, Liu J, Dong Z, Szymura S, Kuang B, Oh E, Neelapu SS, Kwak LW. Development of a Novel Platform for in-Vitro Immune-Monitoring of Antigen-Specific T Cells and Discovery of Novel Antigen-Specific TCRs Using Immortalized B Cells Transfected with mRNA of Antigen Fused to Mitd (IBMAM). American Society of Hematology Blood 140(Suppl 1):4699-4700, 2022. e-Pub 2022.
47. Neelapu SS, Stevens DA, Hamadani M, Frank MJ, Holmes H, Jacobovits A, Hinkle J, Kennedy-Wilde J, Maller O, Weinstein B, Galimi F, Lai RK, Miklos DB. A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies. American Society of Hematology - Blood 140(Suppl 1):4617-4619, 2022. e-Pub 2022.
48. Strati P, Li X, Deng D, Feng L, Sun R, Jallouk A, Adkins S, Cain T, Johncy S, Steiner RE, Ahmed S, Chihara D, Fayad L, Iyer SP, Horowitz SB, Nehlsen R, Nastoupil LJ, Ranjit Nair R, Hassan A, Daoud T, Hawkins M, Samaniego F, Rodriguez MA, Shpall EJ, Kebriaei P, Flowers CR, Hong D, Westin J, Neelapu SS, Green MR. Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma. American Society of Hematology Blood 140(Suppl 1):7493-7495, 2022. e-Pub 2022.
49. Sheng A, Gordon MJ, Ahmed S, Steiner RE, Strati P, Westin J, Hosing C, Kebriaei P, Shpall EJ, Neelapu SS, Nastoupil LJ. Association of the CLL Comorbidity Index (CLL-CI) and International Prognostic Index (IPI) with Overall Survival (OS) and 1-Year Mortality in Patients (pts) with Relapsed or Refractory (r/r) Large B Cell Lymphoma (LBCL) Treated with CD19 Directed Autologous Chimeric Antigen Receptor T (CART) Cell Therapies. American Society of Hematology Blood 140(Suppl 1):2051-2052, 2022. e-Pub 2022.
50. Oluwole OO, Kenderian SS, Shiraz P, Karmali R, Reshef R, McCarthy PL, Ghosh N, Lazaryan A, Filosto S, Poddar S, Mao S, Peng P, Kilcoyne A, Nahas M, Neelapu SS. ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma. American Society of Hematology Blood 140(Suppl 1):10318–10320, 2022. e-Pub 2022.
51. Jain P, Wang Y, Locke FL, Munoz J, Beitinjaneh A, Frank MJ, Dahiya S, Jacobs MT, Hill BT, Lekakis LJ, Miklos DB, Ghobadi A, Neelapu SS, Lin Y, Wang M, Jain MD, Maurer MJ. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: Real-world experience from the United States lymphoma CAR T consortium. ASCO - Journal of Clinical Oncology 40(Suppl 2), 2022. e-Pub 2022.
52. Jain H, Karulkar A, Sharma N, Sengar M, Jaiswal A, Shah S, Khan A, Firfiray A, Asija S, Suvasia P, Suvasia P, Pendhari J, Kalra D, Ravikumar S, Narula G, Banavali S, Poojary M, Hiregoudar S, Nayak L, Bagal B, Tembhare PR, Epari S, Khattry N, Patkar N, Gujral S, Shet T, Subramanian PG, Thorat J, Punatar S, Gokarn A, Ghosh K, Agarwal A, Desai P, Ojha S, Yadav S, Bhosale SP, Rajadhyaksha S, Navkudkar A, Laskar S, Mirgh SP, Nisar A, Pandit D, Patil R, Purwar R, Neelapu SS, Shah NN. Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy. American Society of Hematology Blood 140(Suppl 1), 2022. e-Pub 2022.
53. Locke FL, Neelapu SS, Ray MD, Limbrick-Oldfield EH, Wade SW, Kanters S, Patel AR, Oluwole OO. Network Meta-Analysis (NMA) of Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after 2 Prior Treatments Using Published Comparative Studies. American Society of Hematology Blood 140(Suppl 1):7516-7518, 2022. e-Pub 2022.
54. Agbedia OO, Prakash R, Xu J, Becnel MR, Nair R, Steiner RE, Feng L, Lee HJ, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil LJ, Vo A, Samaniego F, Fowler NH, Saini N, Khouri IF, Im JS, Fayad L, Jain P, Wang ML, Miranda RN, Vega F, Medeiros J, Oki Y, Flowers CR, Neelapu SS, Iyer SP. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis. American Society of Hematology Blood 140(Suppl 1):2313-2315, 2022. e-Pub 2022.
55. Neelapu SS, Chavez J, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Joseph JD, Yan J, Song Q, Peng W, Lui C, Wulff J, Shen RR, Poddar S, Miao H, Beygi S, Jacobson CA. 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). American Society of Hematology Blood 140(Suppl 1):10380-10383, 2022. e-Pub 2022.
56. Nair R, Ayers A, Nastoupil LJ, Gunther JR, Fayad L, Fowler NH, Miranda RN, Hagemeister FB, Lee HJ, Rodriguez MA, Steiner R, Strati P, Nieto Y, Ramdial JL, Chihara D, Wang ML, Malpica Castillo LE, Saini N, Jain P, Pinnix CC, Dabaja BS, Green MR, Flowers CR, Medeiros LJ, Marques-Piubelli ML, Vega F, Noorani M, Ahmed S, Westin J, Neelapu SS, Feng L, Iyer SP. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL. American Society of Hematology Blood 140(Suppl 1):3800-3802, 2022. e-Pub 2022.
57. Lunning MA, H-L W, Z-H H, Locke FL, Siddiqi T, Jacobson CA, Ahmed S, Miklos DB, Lin Y, Hill BT, Ghobadi A, Neelapu SS, Westin J, Miao H, Shahani S, Patel AR, Spooner C, Fu C, Xu H, Pasquini MC. Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy. American Society of Hematology Blood 140(Suppl 1):1852-1855, 2022. e-Pub 2022.
58. Nair R, Prakash R, Dang A, Gunther JR, Huen A, Xu J, Malpica Castillo LE, Cabala CT, Heberton M, Fang P, Ahmed S, Miranda RN, Fayad L, Steiner R, Lee HJ, Chihara D, Jain P, Srour SA, Ramdial JL, Nieto Y, Nastoupil LJ, Pinnix CC, Neelapu SS, Flowers CR, Medeiros LJ, Hosing C, Wang ML, Dabaja BS, Vega F, Feng L, Iyer SP. Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma. American Society of Hematology Blood 140(Suppl 1):12005-12007, 2022. e-Pub 2022.
59. Jallouk A, Feng L, Noorani M, Das K, Steiner RE, Nastoupil LJ, Hawkins M, Nair R, Westin J, Fayad L, Chihara D, Malpica Castillo LE, Iyer SP, Ahmed S, Shpall EJ, Kebriaei P, Neelapu SS, Strati P. Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy. American Society of Hematology Blood 140(Suppl 1):10424-10426, 2022. e-Pub 2022.
60. Oluwole OO, Kenderian SS, Shiraz P, Karmali R, Reshef R, McCarthy PL, Ghosh N, Lazaryan A, Filosto S, Poddar S, Mao D, Peng A, Kilcoyne A, Nahas M, Neelapu SS. ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma. American Society of Hematology Blood 140(Suppl 1):10318-10320, 2022. e-Pub 2022.
61. Pinnix CC, Dabaja BS, Gunther JR, Fang P, Wu S, Ahmed S, Steiner RE, Nair R, Strati P, Westin J, Fayad L, Iyer SP, Rodriguez MA, Lee HJ, Samaniego F, Chihara D, Jain P, Feng L, Flowers CR, Neelapu SS, Nastoupil LJ. Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma. American Society of Hematology Blood 140(Suppl 1):3741–3743, 2022. e-Pub 2022.
62. Tang K, Khwaja R, Feng L, Strati P, Steiner RE, Nair R, Flowers CR, Saini N, Ramdial JL, Srour SA, Champlin RE, Rondon G, Torres J, Kebriaei P, Nastoupil LJ, Mistry H, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Ahmed S. Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy. American Society of Hematology Blood 140(Suppl 1):4684-4685, 2022. e-Pub 2022.
63. H-JJ C, Alig S, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister FB, Rodriguez MA, Lee HJ, McDonnell T, Flowers C, Vega F, Green MR, Alizadeh AA, Richard Davis E, Westin J. Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma. ASCO - Journal of Clinical Oncology 40(Suppl 16), 2022. e-Pub 2022.
64. Mamlouk O, Strati P, Feng L, Sun R, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function. ASCO - Journal of Clinical Oncology 40(Suppl 16), 2022. e-Pub 2022.
65. Khouri IF, Hwang H, Neelapu SS, Wang X, Hosing C, Ahmed S, Kebriaei P, Daher M, Olson AL, Anderlini P, Im JS, Westin J, Shpall EJ, Champlin RE, Nastoupil LJ. Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30. American Society of Hematology Blood 140(Suppl 1):7502-7503, 2022. e-Pub 2022.
66. Li X, Deng Q, Henderson J, Watson G, Deaton L, Cain T, Fayad L, Iyer SP, Hagemeister FB, Nastoupil LJ, Fowler NH, Westin J, Steiner R, Nair R, Ahmed S, Alatrash G, Neelapu SS, Strati P, Green MR. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy. American Society of Hematology Blood 140(Suppl 1):4502–4503, 2022. e-Pub 2022.
67. Neelapu SS, Hamadani M, Miklos DB, Holmes H, Hinkle J, Kennedy-Wilde J, Maller O, Weinstein M, Galimi F, Lai R, Stevens DA. A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B-cell malignancies. ASCO - Journal of Clinical Oncology 40(Suppl 16), 2022. e-Pub 2022.
68. Westin JR, Steiner R, Feng L, Strati P, Flowers CR, Neelapu SS, Nastoupil L, Chihara D, Hagemeister FB, Ahmed S, Nair R, Fayad L, Lee HJ, Rodriguez MA, Davis E, Green MR. Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
69. Spiegel JY, Jain MD, Nastoupil L, Tamaresis J, Ghobadi A, Lin Y, Lekakis LJ, Reagan PM, Oluwole OO, McGuirk JP, Deol A, Sehgal AR, Goy AH, Hill BT, Andreadis C, Muñoz J, Ulrickson ML, Westin JR, Chavez JC, Jacobs MT, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Dahiya S, Lunning MA. Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
70. H-JJ C, Sun R, Yang H, Deng Q, Fayad L, Fowler NH, Parmar S, Ahmed S, Steiner RE, Hagemeister FB, Lee HJ, Nair R, Rodriguez MA, Samaniego F, Iyer SP, Nastoupil L, Neelapu SS, Strati P, Westin JR, Green MR. A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
71. Neelapu SS, Nath R, Munoz J, Tees M, Miklos DB, Frank MJ, Malik SA, Stevens D, Shin CR, Balakumaran A, Loomis-Navale L, Goyal L, Nguyen A, Locke FL. ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
72. Nair R, Feng L, Gunther JR, Xu J, Malpica-Castillo L, Huen A, Torres Cabala C, Heberton M, Fang P, Ahmed S, Miranda RN, Fayad L, Steiner R, Lee HJ, Chihara D, Jain P, Srour SA, Nieto Y, Nastoupil L, Pinnix CC, Neelapu SS, Flowers CR, Medeiros LJ, Hosing C, Wang M, Dabaja BS, Vega F, Iyer SP. Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
73. Jacobson C, Locke FL, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy AH, Muñoz J, Siddiqi T, Shen RR, Bot A, Dong J, Singh K, Spooner C, Karalliyadda R, Kim JJ, Zheng Y, Neelapu SS. Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL). American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
74. Jain N, Ferrajoli A, Thompson PA, Konopleva M, Green MR, Sampath D, Neelapu SS, Takahashi K, Strati P, Burger JA, Kanagal-Shamanna R, Khoury JD, Garg N, Su X, Wang X, Patel H, Ayala A, Kantarjian H, Keating MJ, Wierda WG. Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
75. Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson ML, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt JD, Sherman M, Dong J, Giovanetti A, Yang Y, Lui C, Bashir Z, Jung AS, Jacobson C. Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
76. Malpica-Castillo L, Feng L, Xu J, Nair R, Elias A, Jain P, Chihara D, Steiner R, Fayad L, Samaniego F, Ahmed S, Fowler NH, Nastoupil L, Srour SA, Nieto Y, Hosing C, Miranda RN, Vega F, Pinnix CC, Gunther JR, Fang P, Wu S, Dabaja BS, Medeiros J, Wang M, Neelapu. Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
77. Pinnix CC, Dabaja BS, Gunther JR, Fang P, Wu S, Nastoupil L, Strati P, Nair R, Ahmed S, Steiner RE, Malpica-Castillo L, Chihara D, Jain P, Fayad L, Westin JR, Neelapu SS, Rodriguez MA, Hagemeister FB, Lee HJ, Wang M, Samaniego F, Fowler NH, Flowers CR, Feng L, Chi L, Esmaeli B. Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
78. Jain N, Ferrajoli A, Yilmaz M, Thompson PA, Konopleva, M Green MR, Sampath D, Neelapu SS, Takahashi K, Masarova L, Burger JA, Kanagal-Shamanna R, Khoury JD, Garg N, Su X, Wang X, Patel H, Ayala A, Kantarjian H, Keating MJ, Wierda WG. Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
79. Nair R, Feng L, Gunther JR, Xu J, Malpica-Castillo L, Huen A, Torres Cabala C, Heberton M, Fang P, Ahmed S, Miranda RN, Fayad L, Steiner R, Lee HJ, Chihara D, Jain P, Srour SA, Nieto Y, Nastoupil L, Pinnix CC, Neelapu SS, Flowers CR, Medeiros LJ, Hosing C, Wang M, Dabaja BS, Vega F, Iyer SP. Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
80. Neelapu SS, Hamadani M, Stevens D, Hayes SM, Galimi F, Miklos DB. A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
81. Steiner RE, Strati P, Flowers CR, Neelapu SS, Green MR, Nastoupil L, Hagemeister FB, Feng L, Ahmed S, Nair R, Fayad L, Lee HJ, Rodriguez MA, Westin JR. Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
82. Lekakis LJ, Locke FL, Tees M, Neelapu SS, Malik SA, Hamadani M, Frank MJ, Popplewell LL, Abramson JS, de Vos S, Munoz J, Shin CR, Balakumaran A, Loomis-Navale L, Goyal L, Zhou X, Miklos DB. ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
83. Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedellv PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL). American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
84. Wang Y, Jain P, Locke FL, Munoz J, Maurer MJ, Beitinjaneh A, Frank MJ, Dahiya S, McGuirk JP, Jacobs MT, Goy AH, Vose JM, Hill BT, Oluwole OO, Deol A, Shah BD, Paludo J, Wang T, Lekakis LJ, Miklos DB, Rapoport AP, Ghobadi A, Neelapu SS, Lin Y, Wang M, Jain MD. Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
85. Al Zaki A, Westin JR, Watson G, Feng L, Ahmed S, Mistry H, Nastoupil L, Hawkins M, Nair R, Iyer SP, Lee H, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Strati P. Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
86. Chihara D, Nastoupil L, Strati P, Samaniego F, Feng L, Rodriguez MA, Fayad L, Westin JR, Hagemeister FB, Wang M, Neelapu SS, Fowler NH. Ten Year Follow up of the MD Anderson Cancer Center Phase 2 Study of Rituximab in Combination with Lenalidomide (R2) for Patients with Low Tumor Burden Follicular Lymphoma. American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
87. Song Q, Hu T, Neelapu SS, Locke FL, Jacobson C, Miklos DB, Oluwole OO, Kersten MJ, Topp M, Kim JJ, Singh K, Andrade J, Huang L, Xue A, Schupp M, Nahas M, Shen RR, Bot A. Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events after Axicabtagene Ciloleucel in Large B-Cell Lymphoma Based on Machine Learning Algorithms. American Society of Hematology (Blood) 138(Suppl 15), 2021. e-Pub 2021.
88. Palomba LL, Ghione P, Patel AR, Deighton K, Jacobson C, Nahas M, Scott Jung A, Hatswell AJ, Kanters S, Limbrick-Oldfield E, Wade SW, Snider JT, Neelapu SS, Riberio MT, Gribben J, Radford J, Bobillo S, Ghesquieres H. A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL). American Society of Hematology (Blood) 138(Suppl 1), 2021. e-Pub 2021.
89. H-JJ C, Steiner RE, FAyad L, Strati P, Nair R, Hagemeister FB, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers C, Samaniego F, Rodriguez MA, Feng L, Chuang H, Westin JR. Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
90. Thomas SK, S-C C, Parshottam SP, Rao SS, Olsem JB, Crumpton BN, Szymura S, Wang Z, Anderson A, Feng L, Lee HC Manasanch EE, Patel KK, Weber DM, Orlowski RZ, Neelapu SS, Kwak LW. A Novel Therapeutic DNA Vaccine Elicits Reduction of Tumor Clones and Favorable Perturbations in the Immune Microenvironment in Patients (pts) with Untreated Smoldering Waldenström Macroglobulinemia (sWM). American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
91. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad L, Lee HJ, Iyer SP, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers C, Tummala S, Ramdial J, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
92. Gouni S, Strati P, Westin J, Nastoupil LJ, Steiner RE, Nair R, Fayad L, Neelapu SS, Landgraf R, Bilbao D, Vega F, Agarwal N. Use of Medium Potency Statins Is Associated with Improved Outcomes after Frontline RCHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL). American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
93. Jain P, Yao Y, Zhao S, Liu Y, Hill H, Che Y, Li Y, Jordan AA, McIntosh J, Lee HJ, Steiner RE, Samaniego F, Westin J, Nastoupil LJ, Nair R, Ahmed S, Ok CY, Kanagal-Shamanna R, Oriabure O, Xu G, Chen W, Moghrabi O, McClain CM, Badillo M, Thirumurthi S, Santo D, Iliescu C, Yin CC, Shaoying L, Guilin T, Vega F, Neelapu SS, Flowers C, Wang L, Wang M. Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) – a Phase II Clinical Trial. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
94. Kenderian SS, Oluwole OO, McCarthy PL, Reshef R, Shiraz P, Ahmed O, Gall JL, Nahas M, Tang L, Neelapu SS. ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi‑Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL). American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
95. Munshi PN, Casulo C, Maloney D, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwold OO, Fung HCH, Rosenblatt JD, Rossi JM, Goyal L, Plaks V, Yang Y, Lee J, Godfrey W, Vezan R, Avanzi MP, Neelapu SS. Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
96. Srour SA, Xu J, Al-Juhaishi T, Steiner RE, Ensor J, Ahmed S, Parmar S, Strati P, Nastoupil LJ, Nieto Y, Hosing C, Lee JH, Westin J, Fowler NH, Fayad L, Dabaja BS, Pinnix CC, Gunther JR, Fang P, Samaniego F, Jain P, Champlin RE, Khouri IF, Wang M, Miranda RN, Vega F, Neelapu S, Flowers C, Iyer SP. Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
97. Jacobson CA, Locke FL, Miklos DB, Vose JM, Lin Y, Budde LE, Maloney DG, Jaglowski S, Riedell PA, Lekakis LJ, M-A P, Kim JJ, Kawashima J, Yang Y, Rossi JM, Goyal L, Neelapu SS. Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
98. Neelapu SS, Ulrickson ML, Oluwole OO, Herrera AF, Thieblemont C, Ujjani CS, Lin Y, Riedell PA, Kekre N, deVos S, Yang Y, Milletti F, Goyal L, Kawashima J, Chavez JC. Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL). American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
99. Strati P, Mistry H, Pulsifier B, FAyad L, Ahmed S, Lee JH, Iyer SP, Nair R, Nastoupil LJ, Parm S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Dabaja Bouthaina BS, Noorani M, Claussen CM, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Neelapu SS. Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
100. Iyer SP, Xu J, Becnel MR, Nair R, Steiner R, Feng L, Lee HJ, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil LJ, Vo A, Samaniego F, Fowler NH, Saini N, Khouri IF, IM JS, Jain P, Fayad L, Wang M, Miranda RN, Vega F, Flowers C, Neelapu SS. A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
101. Chavez JC, Jacobson CA, Sehgal AR, Neelapu SS, Maloney DG Salles G, William BM, Yang Y, Goyal L, Chou J, Plaks V, Avanzi MP. Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
102. Strati P, Samaniego F, Gallardo M, Noorani M, Hagemeister FB, Westin JR, Lee HJ, Rodriguez MA, Neelapu SS, Gunther JR, Kangal-Shamanna R, Vega F, Fowler NH, Flowers CR, Nastoupil LJ. Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
103. Saini N, C-C C, Strati P, Natoupil LJ, Westin J, Nair R, FAyad L, Ahmed S, Lee HJ, Iyer SP, Steiner RE Greenbaum U, Kebriaei P, Shpall EJ, Jain N, Green MR, Ajami NJ, Flowers C, Champlin RE, Wargo J, Neelapu SS, Jeng RR. Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
104. Galon J, Scholler N, Perbost R, Turcan S, Danan C, Lundry Locke F, Neelapu SS, Miklos DB, Jacobson CA, Lekakis LJ, Lin Y, Ghobadi A, Chou J, Wang Z, Xue A, Rossi JM, Bot A. Tumor microenvironment associated with increased pretreatment density of activated PD-1+ LAG-3+/− TIM-3− CD8+ T cells facilitates clinical response to axicabtagene ciloleucel (axi-cel) in patients (pts) with large B-cell lymphoma. Journal of Clinical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
105. Nair R, Pinnix CC, Gunther JR, Strati P, Westin J, Fayad L, Hagemeister FB, Iyer SP, Nastoupil LJ, Parmar S, Rodriguez MA, Steiner R, Dabaja BS, Fang P, Flowers C, Noorani M, Feng L, Neelapu SS, Ahmed S, Lee HJ. M.D. Anderson experience of immune checkpoint inhibitor therapy in classical Hodgkin lymphoma. Journal of Cliniical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
106. Ahmed S, Furqan F, Strati P, Westin J, Fayad L, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner R, Wang M, Pinnix CC, Flowers C, Horowitz SB, Hawkins M, Neelapu SS. . Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel). Journal of Clinical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
107. Lundry Locke F, Bartlett NL, Jacobson CA, Oluwole OO, Munoz J, Lekakis LT, Topp MS, Avivi I, Kim JJ, Chu R, Zheng L, Rossi JM, Bot A, Neelapu SS. Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1. Journal of Clinical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
108. Neelapu SS, Munoz J, Lundry Locke F, Miklos DB, Brown R, McDevitt JT, Mardiros A, Demirhan E, Konto C, Tees MT. First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study. Journal of Clinical Oncology (ASCO) 38(Suppl 1), 2020. e-Pub 2020.
109. Strati P, Furqan F, Westin J, Fayad L, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Simrit Parmar S, Rodriguez MA, Samaniego F, Steiner R, Wang M, Pinnix CC, Flowers C, Horowitz SB, Classen C, Mistry H, Neelapu SS. Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel). Journal of Clinical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
110. Chin CK, Lim KJC, Lewis KL, Jain P, Yg Q, Feng L, Cheah C, Seymour JF, Ritchie D, Burbury K, Si Lun Tam C, Fowler NH, Fayad L, Westin J, Neelapu SS, Hagemeister FB, Samaniego F, Flowers C, Nastoupil LJ, Dickinson M. Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: An international, multicenter propensity matched study. Journal of Clinical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
111. Chin CK, Cheah C, Jain P, Fowler NH, Fayad L, Westin J, Rodriguez MA, Noorani M, Neelapu SS, Hagemeister FB, Medeiros LJ, Vega F, Samaniego F, Flowers C, Nastoupil L. Clinicopathologic features and outcomes of de novo transformed indolent lymphoma. Journal of Clinical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
112. Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles GA, Casulo C, Munshi PN, Maloney DG, De Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HC, Plaks V, Yang Y, Lee J, Avanzi MP, Neelapu SS. Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL). Journal of Clinical Oncology (ASCO) 38(Suppl), 2020. e-Pub 2020.
113. Neelapu SS, Chavez JC, Lin Y, Munoz L, Ujjani CS, Riedell P, De Vos S, Oluwole OO, Kekre N, Yang Y, Goyal L, Backhouse K, Milletti F, Kawashima J, Francisco Herrera A. ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL). Journal of Clinical Oncology 37(Suppl), 2019. e-Pub 2019.
114. Spiegel JY, Dahiya S, Jain MD, Nastoupil LJ, Ghobadi A, Lin Y, Lunning MA, Reagan PM, McGuirk J, Deol A, Munoz J, Locke FL, Neelapu SS, Tamaresis JS, Rapoport A, Miklos DB, Hill BT. Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US lymphoma CAR-T consortium. Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
115. Abbas H, Alfayez M, Garcia-Manero G, Ravandi F, Kadia TM, Dinardo CD, Mathews J, Flores W, Andreeff M, Kornblau SM, Konopleva M, Cortes JE, Neelapu SS, Kantarjian HM, Davis RE, Guastad Daver N. IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): A subset analysis of a phase 2 study. Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
116. Strati P, Adkins S, Nastoupil LJ, Westin J, Hagemeister FBH, Fowler NH, Lee HJ, Fayad L, Samaniego F, Ahmed S, Varma A, Arafat S, Johncy S, Kebriaei P, Mulanovich V, Ariza-Heredia E, Neelap SS. Hematopoietic recovery and immune reconstitution after axi-cel CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma. Jpurnal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
117. Anand K, Burns E, Sano D, Pingali SR, Westin J, Nastoupi LJ, Lee HJ, Samaniego F, Parmar S, Wang M, Hawkins M, Adkins S, Fayad L, Steiner S, Nair R, Ahmed S, Fowler NH, Neelapu SS, Iyer SP. Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS. Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
118. Strati P, Ahmed MA, Fowler NH, Hagemeister FB, Fayad L, Rodriguez MA, Samaniego F, Wang M, Westin J, Romaguera JE, Noorani M, Phansalkar K, Cheah C, Feng L, Davis RE, Nastoupil LJ, Neelapu SS. Prognostic value of baseline SUVmax in patients with advanced stage follicular lymphoma receiving frontline rituximab-based therapy. Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
119. Thomas SK, Cha S, Parshottam SP, Rao SS, Olsem JB, Crumpton BN, Feng L, Lee HC, Manasanch EE, Weber DM, Patel KK, Orlowski RZ, Neelapu SS, Kwak LW. Phase I trial of a novel DNA vaccine in patients (pts) with smoldering Waldenstrom macroglobulinemia (sWM). Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
120. Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Srour S, Bashir Q, Qazilbash MH, Weber DM, Neelapu SS, Orlowski RZ, Feng L, Lin P, Manasanch EE. Correlation of minimal residual disease negativity (MRD-) with prognosis in high-risk myeloma (HRM). Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
121. Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, Bartlett NL, Braunschweig I, Jiang Y, Kim JJ, Zheng L, Rossi JM, Lundry Locke F. Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B cell lymphoma (LBCL). Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
122. Westin JR, Nastoupil LJ, Fayad L, Hagemeister FB, Oki Y, Turturro F, Ahmed S, Rodriguez MA, Lee HJ, Steiner RE, Nair R, Parmar S, Young KH, McDonnell TJ, Chuang H, Green MR, Neelapu SS, Davis E. Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma. Journal of Clinical Oncology (ASCO) 37(Suppl), 2019. e-Pub 2019.
123. Lundry Locke F, Ghobadi A, Lekakis LL, Miklos DB, Jacobson CA, Jacobsen ED, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Reagan PM, Farooq U, Deol A, Bot A, Rossi JM, Jiang Y, Xue A, Go WY, Neelapu SS. Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. Journal of Clinical Oncology 36(Suppl), 2018. e-Pub 2018.
124. Locke FL, Ghobadi A, Jacobson CA, Jacobsen ED, Miklos DB, Lekakis LJ, Braunschweig I, Oluwole OO, Lin Y, Siddiqi T, Deol A, Reagan PM, Farooq U, Bot A, Jiang Y, Rossi JM, Xue A, Go WY, Neelapu SS. Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. Journal of Clinical Oncology (ASCO) 36(Suppl), 2018. e-Pub 2018.
125. Hermanson D, Barnett BE, Rengarjan S, Codde R, Martin CE, Wang X, Tan Y, Smith JB, He J, Mathur R, Neelapu SS, Yang J, Ostertag EM, Devon SJ. PiggyBac-manufactured anti-BCMA Centyrin-based CAR-T therapeutic. Proceedings of the American Association for Cancer Research 58, 2017. e-Pub 2017.
126. Qin H, Wei G, Sakamaki I, Dong Z, Cheng WA, SmithDL, Wen F, Sun H, Cha S, Neelapu SS, Kwak LW. Drug resistant B-cell tumors eliminated by novel therapeutic antibodies. Proceedings of the 110th Annual Meeting of the American Association for Cancer Research 58, 2017. e-Pub 2017.
127. Overman MJ, Lopez CD, Benson AB, Neelapu SS, Mettu NB, Ko AH, Chung VM, Nemunaitis JJ, Reeves JA, Bendell JC, Philip PA, Dalal R, Fardis M, Greer J, Wang X, Inamdar S, Lannutti BJ, Rothbaum W, Izumi R, Javle MM. A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC). J Clin Oncol (ASCO Annual Meeting 2016) 34((suppl; abstr 4130)), 2016. e-Pub 2016.
128. Neelapu SS, Locke FL, Bartlett NL, Siddiqi T, Chavez JC, Hosing C, Cashen AF, Budde L, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Wiezorek JS, Go WY. Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL). J Clin Oncol (ASCO Annual Meeting 2016) 34((suppl; abstr 7559)), 2016. e-Pub 2016.
129. Crump M, Neelapu SS, Farooq U, Den Neste EV, Kuruvilla J, Ahmed MA, Link BK, Hay AE, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek JS, Go WY, Gisselbrecht C. Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study. J Clin Oncol (ASCO Annual Meeting 2016) 34((suppl; abstr 7516)), 2016. e-Pub 2016.
130. Issa A, Sathyanarayanan V, Fanale MA, Oki Y, Hagemeister FB, Neelapu SS, Nastoupil LJ, Fowler NH, Turturro F, Noorani M, Ahmed MA, Davis RE, Rodriguez MA, Wang M, Feng L, Young KH, McDonnell T, Pinnix CC, Fayad L, Westin JR. Outcomes of diffuse large b-cell lymphoma with MYC and/or BCL2 protein expression treated with intensive chemotherapy. J Clin Oncol (ASCO Annual Meeting 2016) 34((suppl; abstr 7563)), 2016. e-Pub 2016.
131. Westin JR, Oki Y, Fayad L, Nastoupil LJ, Turturro F, Hagemeister FB, Sathyanarayanan V, Young KH, McDonnell T, Chuang H, Zhou S, Neelapu SS, Davis RE. Rituximab, lenalidomide, and ibrutinib alone and combined with dose adjusted chemotherapy for patients with high risk diffuse large B-cell lymphoma. J Clin Oncol (ASCO Annual Meeting 2016) 34((suppl; abstr TPS7575)), 2016. e-Pub 2016.
132. Ghobadi A, Locke FL, Neelapu SS, Siddiqi T, Chavez JC, Hosing CM, Bartlett NL, Budde LE, Bot A, Rossi JM, Sherman M, Navale L, Elias M, Wiezorek J, Go WY. Updated phase I results from ZUMA-1: a phase I-II multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive non-Hodgkin lymphoma (NHL). Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, 2016. e-Pub 2016.
133. Sehgal L, Jain N, Khashab T, wang X, Neelapu S, Samaniego F. Targeting mir101/ EZH2/NFkb axis by FGFR1 inhibitor in mantle cell lymphoma. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, 2016. e-Pub 2016.
134. Takahashi K, Wang F, Kantarjian H, Denaha D, Thompson E, Gumbs C, Patel K, Neelapu S, Wang Y, Bohannan Z, DiNardo C, Ravandi F, Estrov Z, Colla S, Zhang J, Wu X, Garcia-Manero G, Futreal A. Clonal origin of therapy-related myeloid neoplasms. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, 2016. e-Pub 2016.
135. Fowler N, Nastoupil L, Neelapu S, Turturro F, Hagemeister F, Kwak LW, Romaguera J, Fanale M, Fayad L, Forbes S, Khan J, Samaniego F, Cheah C. Lenalidomide and Obinutuzumab in previously treated indolent lymphoma, Results of a Phase I Dose Escalation Study. Hematol Oncol (13th International Conference on Malignant Lymphoma) 33:1-365(Abstr 342), 2015. e-Pub 2015.
136. Younes A, Patel MR, Oki Y, Flinn IW, Gerecitano JF, Neelapu SS, Copeland A, Akins AJ, Clancy MS, Viner J, Wang J, Atoyan R, Berdeja JG. A First-in-Human Trial of CUDC-907, an Oral, First-in-Class, Dual Inhibitor of PI3K and HDAC, in Patients with Refractory/Relapsed Lymphoma and Multiple Myeloma. Hematol Oncol (13th International Conference on Malignant Lymphoma) 33:1-365(Abstr 80), 2015. e-Pub 2015.
137. Fowler N, Cheah C, Neelapu S, Nastoupil L, Turturro F, Hagemeister F, Kwak LW, Romaguera J, Fanale M, Fayad L, Claret L, Feng E, Davis RE, Samaniego F. Extended dosing lenalidomide with intensified rituximab in untreated indolent NHL. Hematol Oncol (13th International Conference on Malignant Lymphoma) 33:1-365(Abstr 192), 2015. e-Pub 2015.
138. Samaniego F, Mathur R, Sehgal L, Neelapu S. FGF Signaling supports mantle cell lymphoma survival in the presence of mesenchymal stromal cells. Hematol Oncol (13th International Conference on Malignant Lymphoma) 33:1-365(Abstr 167), 2015. e-Pub 2015.
139. Cheah C, Ahmed M, Davis R, Nastoupil L, Chihara D, Kwak LW, Fayad LE, Phansalkar K, Samaniego F, Neelapu SS, Fowler NH. Comparison of lenalidomide and rituximab with chemoimmunotherapy in patients with untreated grades 1-2 follicular lymphoma treated at the MD Anderson Cancer Center. Hematol Oncol (13th International Conference on Malignant Lymphoma) 33:1-365(Abstr 191), 2015. e-Pub 2015.
140. Ahmed MA, Chihara D, Vargas N, Ma L, Fayad LE, Oki Y, Hagemeister FB, Romaguera JE, Turturro F, Fowler N, Rodriguez MA, Samaniego F, Fanale MA, Nastoupil L, Wang M, Lee HJ, Kwak LW, Noorani M, Davis RE, Westin JR, Neelapu SS. Outcome of relapsed/refractory diffuse large B-cell lymphoma after second salvage therapy: MD Anderson experience. Hematol Oncol (13th International Conference on Malignant Lymphoma) 33:1-365(Abstr 375), 2015. e-Pub 2015.
141. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros J, Fanale MA, Hagemeister FB, Fayad L, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler N, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of Hyper-CVAD with pegylated liposomal doxorubicin alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with newly diagnosed T- and NK-cell lymphoma (T/NKCL). J Clin Oncol (ASCO Annual Meeting 2015) 33(Suppl; Abstr 8538), 2015. e-Pub 2015.
142. Berdeja JG, Oki Y, Patel MR, Flinn I, Neelapu SS, Clancy MS, Viner J, Wang J, Younes A. Phase 1 first-in-human trial of oral CUDC-907, a dual inhibitor of PI3K and HDAC, in patients with refractory/relapsed lymphoma or multiple myeloma. J Clin Oncol (ASCO Annual Meeting 2015) 33(Suppl; Abstr 8537), 2015. e-Pub 2015.
143. Mathur R, Sehgal L, Berkova Z, Neelapu SS, Samaniego F. Inhibition of demethylase, JMJD3 sensitizes diffuse large B-cell lymphoma (DLBCL) to chemotherapy. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015. e-Pub 2015.
144. Yang Q, Chen LS, Neelapu SS, Gandhi V. Idelalisib impacts cell growth through inhibiting translation regulatory machineries in mantle cell lymphoma. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015. e-Pub 2015.
145. Sehgal L, Mathur R, Berkova Z, Khashab T, Wang X, Romaguera J, Rodriguez AE, Neelapu S, Samaniego F. Tumor microenvironment influences survival of mantle cell lymphoma-initiating cells through FGF/FGFR1 signaling. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, 2015. e-Pub 2015.
146. Phansalkar K, Ahmed MA, Fowler N, Ma L, Noorani M, Lee ST, Feng L, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale MA, Wang M, Oki Y, Turturro F, Westin JR, Nastoupil LJ, Kwak LW, Davis RE, Neelapu SS. R-Bendamustine Vs R-CHOP As Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis. Proceedings of 56th American Society of Hematology Annual Meeting 124(21), 2014. e-Pub 2014.
147. Nastoupil LJ, Neelapu SS, Samaniego F, Hagemeister FB, Romaguera JE, Kwak LW, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Mclaughlin P, Fowler, NH. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. Proceedings of the 50th American Society of Clinical Oncology Annual Meeting, 2014. e-Pub 2014.
148. Janku F, Oki Y, Falchook GS, Subbiah V, Naing A, Bravo VMV, Hong DS, Westin JR, Nunez C, Fayad L, Neelapu SS, Kwak LW, Shpall EJ, Wheler JJ, Barnes T, Liang WS, Salhia B, Meric-Bernstam F, Kurzrock R, Fanale MA. Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. Proceedings of the 50th American Society of Clinical Oncology Annual Meeting, 2014. e-Pub 2014.
149. Thomas SK, Melendez AG, Feng L, Wang M, Neelapu SS, Shah JJ, Orlowski RZ, Weber DM. Phase I trial of pomalidomide (P) in patients (pts) with relapsed and/or refractory (R/R) Waldenström's macroglobulinemia (WM). Proceedings of the 50th American Society of Clinical Oncology Annual Meeting, 2014. e-Pub 2014.
150. Sarkar AK, Balakrishnan K, Ayres M, Neelapu SS, Gandhi V. Essential role of ataxia telangiectasia in mitochondrial autophagy in mantle cell lymphoma. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research:313, 2014. e-Pub 2014.
151. Yang Q, Chen LS, Neelapu SS, Gandhi V. The PI3Kδ inhibitor, idelalisib, inhibits transcription and translation through PI3K/Akt pathway in mantle cell lymphoma. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research:4529, 2014. e-Pub 2014.
152. Westin R, Chu F, Fayad L, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, Davis RE, Neelapu SS. Phase II Safety and Efficacy Study of Pidilizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Hematol Oncol 31(Suppl. I):150, 2013. e-Pub 2013.
153. Samaniego F, Romaguera J, Fowler N, Fanale M, Pro B, Shah J, McLaughlin P, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu S, Kwak L. A single center phase II trial of 90Yttrium-ibritumomab-tiuxetan produces high response rates as first-line therapy for early stage B-cell indolent lymphoma including bulky disease. Hematol Oncol 31(Suppl. I):163, 2013. e-Pub 2013.
154. Yang Q, Chen LS, Neelapu SS, Lanutti BJ, Gandhi V. PI3Kδ inhibitor, GS-1101, impacts transcription and translation in mantle cell lymphoma. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013, 2013. e-Pub 2013.
155. Sarker A, Chen J, Neelapu SS, Balakrishnan K, Gandhi V. L14R8, a Pac derivative, induces casapase-3 mediated apoptosis in mantle cell lymphoma. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013, 2013. e-Pub 2013.
156. Fowler N, Mclaughlin P, Fisch M, Dakhil S, Bury M, Fayad L, Shah J, Neelapu S, Romaguera J, Rodriguez D, Ayala A, Kwak L. Rituximab plus sargramostim for the treatment of. Annals of Oncology 11th International Conference on Malignant Lymphoma 22(Suppl 4), 2011. e-Pub 2011.
157. Fowler N, Hagemeister F, Mclaughlin P, Kwak L, Romaguera J, Fanale M, Neelapu S, Fayad L, Orlowski R, Wang M, Pro B, Lacerte L, Samaniego F. Lenalidomide plus rituximab is a highly effective and well-tolerated biologic therapy in untreated indolent b cell non-hodgkins lymphoma. Annals of Oncology 11th International Conference on Malignant Lymphoma 22(Suppl 4), 2011. e-Pub 2011.
158. Wang M, Fayad L, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M, Younes A, Cabanillas F, Zhang L, Champlin R, Kwak L, Feng L, Bell N, Zeldis J, Romaguera J. Oral lenalidomide plus 4 doses of rituximab. Annals of Oncology 11th International Conference on Malignant Lymphoma 22(Suppl 4), 2011. e-Pub 2011.
159. Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, Caraway N, Neelapu SS, Kwak LW, Simmons P, McCarty N. Prospective isolation of clonogenic mantle cell lymphoma initiating cells. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research, 2010. e-Pub 2010.
160. Rawal S, Park HJ, Foglietta M, Nattamai D, Chou T, Kannan S, Neelapu SS. TH2 cells interact with tumor cells to facilitate recruitment of regulatory T cells into the tumor microenvironment in human B-cell lymphomas. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research, 2010. e-Pub 2010.
161. Kannan S, Neelapu SS. Meta-analysis of multiple follicular lymphoma GEO datasets reveals the significance of tumor microenvironment in disease progression. Proceedings of the 100th Annual Meeting of AACR, 2009. e-Pub 2009.
162. Rawal S, Park HJ, Foglietta M, Nattamai D, Kwak LW, Neelapu SS. Active recruitment of regulatory T cells into follicular lymphoma tumor microenvironment. Proceedings of the 100th Annual Meeting of AACR, 2009. e-Pub 2009.
163. Cha SC, Qin H, Wu W, Kannan S, Ong J, Wei J, Kwak B, Kim SJ, Gold D, Kwak LW, Neelapu SS. Follicular lymphoma B-cell receptors recognize vimentin: Implications for lymphomagenesis. Proceedings of the 100th Annual Meeting of AACR, 2009. e-Pub 2009.
164. Lee ST, Park KU, Nattamai D, Cha SC, Qin H, Kwak LW, Neelapu SS. Activation of follicular lymphoma tumor cells with TLR9 agonist and CD40 ligand facilitates rapid and efficient generation of lymphoma-specific T cells. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, 2008. e-Pub 2008.
165. Rawal S, Cha SC, Qin H, Kwak LW, Neelapu SS. Stat6 is constitutively activated in human follicular lymphoma. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, 2008. e-Pub 2008.
166. Wang M, Fayad L, Hagemeister F, Neelapu SS, Bell N, Byrne C, Knight R, Zeldis J, Kwak L, Romaguera J. A phase I/II study of lenalidomide ( Len) in combination with rituximab in ( R) relapsed/refractory mantle cell lymphoma (MCL). J Clin Oncol (Proceedings, Annual ASCO Meeting-P-Part 1, 2007) 25(18S):8030, 2007. e-Pub 2007.
167. Younes A, Fanale M, Pro B, McLaughlin P, Neelapu SS, Fayad L, Wedgwood W, Dubay M, Martell RE. A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (Proceedings of the Annual ASCO Meeting-Part 1, 2007) 25(18S):8000, 2007. e-Pub 2007.
168. Voo KS, Bover LDC, Neelapu SS, Kwak LW, Liu YF. OX40-ligand inhibits function of IL-10 producing intratumoral CDr+CD25+ regulatory T cells in human follicular B-cell lymphoma. J Immunol (Proceedings of the American Association of Immunologists Annual Meeting) 178:50:25, 2007. e-Pub 2007.
169. Samaniego F, Fayad LE, Pro B, McLaughlin P, Rodriguez MA, Hagemeister FB, Fanale M, Neelapu SS, Younes A, Kwak LW. Pentostatin combined with cyclophosphamide and rituximab induces high response rates in patients with untreated indolent B-cell lymphoma. Proceedings of the 48th ASH Annual Meeting, 2006. e-Pub 2006.
170. Freedman AS, Hamlin PA, Neelapu SS, Nichols C, Robertson M, Bergier G, Winter JN, Polikoff J, Lin T, Pohlman B, Esquiel V, Melink T, Bender J. Phase III trial of active immunotherapy (Favld, Id/KLH) following rituximab induction therapy: clinical responses in patients (pts) with follicular non-Hodgkin's lymphoma (NHL).l. Proceedings of the 48th ASH Annual Meeting, 2006. e-Pub 2006.
171. Younes A, Fayad LE, Goy A, McLaughlin P, Pro B, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Kwak L, Neelapu S, Medeiros J, Wedgebood A, Fanale M. Results of rituximab plus ABVD in 65 newly diagnosed patients with classical Hodgkin's lymphoma: Improvement of event free survival (EFS) in all international prognostic score (IPS) groups. Proceedings of the 48th ASH Annual Meeting, 2006. e-Pub 2006.
172. Lee ST, Liu S Sukhumalchandra P, Molldrem J, Hwu P, Liu YJ, Kwak LW, Lizee G, Neelapu SS. A novel strategy for generation of human tumor-specific T-cell clones for adoptive transfer. Proceedings of the 48th ASH Annual Meeting, 2006. e-Pub 2006.
173. Wang M, Oki, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu SS, Podoloff D, Samuels B, Loyer E, Zhou Y, Younes A. Phase II study of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) in patients with relapsed and refractory mantle cell lymphoma (MCL). Proceedings of the 48th ASH Annual Meeting, 2006. e-Pub 2006.
174. Ishiyama K, Kondo Y, Weider E, Lu S Martin-Orozco N, Dong C, Neelapu SS, Hwu P, Liu YJ, Kwak L, Molldrem J. High avidity PD-1 cyclin E-specific CTL contribute to leukemia remission and may be induced by epitope spread. Proceedings of the American Association of Immunologists Annual Meeting, Boston, MA, 2006. e-Pub 2006.
175. Neelapu SS, Lee ST, Wang YH, Sukhumalchandra P, Molldrem J, Weider E, Radvanyi L, Hui P Liu YJ, Kwak LW. A novel strategy for efficient cloning of human tumor-specific T cells. Proceedings of the American Association of Immunologists Annual Meeting, Boston, MA, 2006. e-Pub 2006.
176. Martin-Orozco N, Neelapu SS, Lee ST, Wang Y, Ito T, Molldrem J, Liu YJ, Dong C, Kwak L. T-cell co-inhibitory molecules and the response to human B-cell malignancies. Proceedings of the American Association of Immunologists Annual Meeting, Boston, MA, 2006. e-Pub 2006.
177. Gause BL, Neelapu SS, Cohen CM, Katz LM, Watson T, Stergiou AM, Kwak LW. Idiotype vaccine therapy of follicular lymphoma in first remission:Association of t(14;18) and disease-free survival in a phase II cohort. Proceedings of the 42nd ASCO Annual Meeting, 2006. e-Pub 2006.
178. Qin H, Sudhir KP, Cha SC, El-Bereir S, Neelapu SS, Roy K, Kwak LW. Development of a novel, injectable microparticle lymphoma DNA vaccine. Proceedings of the 97th AACR Annual Meeting, 2006. e-Pub 2006.
179. Romaguera JE, Fayad LE, Wang M, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez A, Younes A, Neelapu SS, Kwak L, Goy AH, Beasley V. High (95%) response rates in relapsed/refractory mantle cell lymphoma after R-HCVAD alternating with R-methotrexate/cytarabine (R-M-A). Proceedings of the 47th ASH Annual Meeting, 2005. e-Pub 2005.
180. Cha SC, Biragyn A, Ruffini PA, Qin H, Neelapu SS, Kwak LW. Cloning of B cell lymphoma-associated antigens using modified phage displayed expression cDNA library and immune patient sera. Proceedings of the 47th ASH Annual Meeting, 2005. e-Pub 2005.
181. Younes A, Pro B, Rodriguez MA, Romaguera JE, McLaughlin P, Wang M, Hagemeister F, Dang NH, Neelapu S, Podoloff D. Activity of Yttrium90 (90Y) Ibritumomab Tiuxetan (Zevalin) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL). Proceedings of the 47th ASH Annual Meeting, 2005. e-Pub 2005.
182. Lee ST, Jiang YF, Cha SC, Qin H, Kwak LW, Neelapu SS. In vitro expansion of autologous follicular lymphoma-specific T cells for adoptive transfer. Proceedings of the 47th ASH Annual Meeting, 2005. e-Pub 2005.
183. Younes A, McLaughlin P, Fayad LE, Goy A, Romaguera JE, Pro B, Rodriguez MA, Samaniego F, Kwak L, Neelapu SS, Medeiros J. Six weekly doses of rituximab plus ABVD for newly diagnosed patients with advances stage classical Hodgkin's lymphoma: depletion of reactive B-cells from the microenvironment by Rituximab. Proceedings of the 47th ASH Annual Meeting, 2005. e-Pub 2005.
184. Dang NH, McLaughlin P, Fayad L, Romagera J, Hagemeister F, Younes A, Neelapu S, Samaniego F, Jones D, Walker PL, Rodriguez MA, Kwak L, Pro B. Interim analyses of a phase II study of the combination of Denileuken Difitox (Ontak) and Rituximab for relapsed/refractory B-cell non-Hodgkin's lymphoma. Proceedings of the 47th ASH Annual Meeting, 2005. e-Pub 2005.
185. Dang NH, Pro B, Hagemeister F, Samaniego F, Jones D, Rodriguez M, Goy A, Romaguera J, Walker PL, Younes A, Neelapu SS, Kwak L, Fayad L. Phase II study of Denileukin Difitox (Ontak) for relapsed/refractory non-Hodgkin's lymphoma. Proceedings of the 47th ASH Annual Meeting, 2005. e-Pub 2005.
186. Neelapu SS, Munshi NC, Jagannath S, Watson TM, Pennington R, Barlogie B, Kwak LW. Tumor Antigen Immunization of Sibling Stem Cell Transplant Donors in Multiple Myeloma. Proceedings of the 46th American Society of Hematology Annual Meeting, 2004. e-Pub 2004.
187. Neelapu SS, Gause BL, Harvey L, Frye RA, Horton J, Robb RJ, Popescu MC, Kwak LW. Human autologous tumor-specific T-cell responses induced by liposome encapsulated lymphoma membrane proteins. Proceedings of the 46th American Society of Hematology Annual Meeting, 2004. e-Pub 2004.
188. Bishop MR, Neelapu SS, Fowler DH, Krumlauf M, Gress R, Kwak LW. Preliminary Results of Sibling Donor Immunization with Patient-Derived Id-KLH Vaccine Prior to Reduced-Intensity Allogeneic Stem Cell Transplantation for Multiple Myeloma. Proceedings of the 46th American Society of Hematology Annual Meeting, 2004. e-Pub 2004.
189. Janik JE, Morris JC, Quinn C, Gao W, Waldmann TA, Wilson WH, Kwak LW, Pittaluga S, Neelapu S, Streicher H, Berzofsky JA, Dahut W, Arlen P, Gulley JL, Schlom J, Davis TA, Lowy I. A Pilot Study of MDX-010 after Vaccine Failure in Patients with Advanced Malignancy. Proceedings of the 45th American Society of Hematology Annual Meeting, 2003. e-Pub 2003.
190. Neelapu SS, Gause BL, Nikcevich DA, Schuster SJ, Winter J, Gockerman JP, Sotomayor E, Inghirami G, Muggia F, Watson TM, Snow S, Kubovic P, Ferraro M, Jaffe ES, Reynolds CW, Kwak LW. Vaccine therapy of follicular lymphoma in first remission: Long-term follow-up of phase II results and high rate of chemotherapy-induced complete remissions in a controlled, randomized phase III trial. Proceedings of the 45th American Society of Hematology Annual Meeting, 2003. e-Pub 2003.
191. Wilson WH, Neelapu S, Rosenwald A, White T, Dunleavy K, Pittaluga S, Hakim F, Stetler-Stevenson M, Steinberg S, Jaffe ES, Gress R, Wright G, Staudt L, Janik J, Kwak L. Idiotype Vaccine and Dose-Adjusted EPOCH-Rituximab Treatment in Untreated Mantle Cell Lymphoma: Preliminary Report on Clinical Outcome and Analysis of Immune Response. Proceedings of the 45th American Society of Hematology Annual Meeting, 2003. e-Pub 2003.
192. Neelapu SS, Wilson WH, Baskar S, White T, Frye R, Pennington R, Kwak LW. Induction of T cell responses by tumor antigen vaccination in mantle cell lymphoma following rituximab-based treatment. Proceedings of the 39th American Society of Clinical Oncology Annual Meeting, 2003. e-Pub 2003.
193. Neelapu SS, Baskar S, Harvey L, Kwak LW. A novel strategy for efficient in vitro priming of T cells against a tumor antigen. . Proceedings of the 94th American Association for Cancer Research Annual Meeting,, 2003. e-Pub 2003.
194. Neelapu SS, Baskar S, Gause BL, Watson TM, Frye AR, Pennington R, Popescu MC, Robb R, Kwak LW. Clinical trial of a second generation lymphoma vaccine. Proceedings of the 93rd AACR Annual Meeting, 2002. e-Pub 2002.

Book Chapters

1. Greenbaum, U, Ramdial, JL, Afrough, A, Alsfeld, LC, Ghanem, S, Daher, M, Olson, AL, Kebriaei, P, Strati, P, Steiner, RE, Ahmed, S, Tanner, MR, Neelapu, SS, Rezvani, K, Shpall, E. Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy, 509-524, 2023.
2. Sullivan, TJ, Whitehead, K, Williamson, R, Grimes, D, Schlect, D, Brown, I, Dickie, G, Bhatia, S, Paulino, AC, Buatti, JM, Mayr, NA, Wen, BC, Pinnix, CC, Dabaja, BS, Milgrom, SA, Smith, GL, Abou, Z, Nastoupil, L, Romaguera, JE, Turturro, F, Fowler, N, Fayad, LE, Westin, JR, Neelapu, SS, Fanale, MA, Rodriguez, MA, Hagemeister, FB, Lee, HJ, Oki, Y, Wang, L, Samaniego, F, Chi, L, Esmaeli, B. Orbital adnexal lymphoma. In: Foundational Papers in Oculoplastics. Springer, Cham, 375-388, 2022.
3. Selli, ME, Dalal, P, Neelapu, SS, Singh, N. Mechanisms of Resistance and Relapse After CAR-T Cell Therapy. In: Gene and Cellular Immunotherapy for Cancer. Humana, Cham, 207-219, 2022.
4. Puebla-Osorio N, Strati P, Neelapu SS. The Microenvironment in Follicular Lymphoma. In: Follicular Lymphoma: Current Management and Novel Approaches. Springer, 2019.
5. Neelapu SS. Indolent B-Cell Non-Hodgkin Lymphomas. In: Sixty Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center, 2013.
6. Kassim AA, Neelapu SS, Kwak LW, Kaer LV. Immunotherapy. In: Wintrobe’s Clinical Hematology. 13th Edition, 2013.
7. Qin H, Neelapu SS, Cha SC, Kwak LW. Vaccine Therapies. In: The Lymphoid Neoplasms. 3rd edition. Edward Arnold Company, 2010.
8. Neelapu SS, Kwak LW. Principles of Vaccine Therapy. In: William’s Hematology. 8th edition, 2010.
9. Neelapu SS, Dunbar CE. Multiple Myeloma. In: Bethesda Handbook of Clinical Oncology. 3rd edition, 2010.
10. Kassim AA, Neelapu SS, Kwak LW, Van Kaer L. Immunotherapy. In: Wintrobe's Clinical Hematology. 12th edition, 2008.
11. Neelapu SS, Dunbar CE. Multiple Myeloma. In: Bethesda Handbook of Clinical Oncology. 2nd edition, 2005.
12. Neelapu SS, Kwak LW. Vaccine Approaches to non-hodgkin’s lymphoma therapy, Malignant Lymphomas. In: American Cancer Society Atlas of Clinical Oncology, 2002.
13. Neelapu SS, Dahut W. Bladder cancer. In: Bethesda Handbook of Clinical Oncology. 1st edition, 2000.

Patents

1. Neelapu SS, Casellas R, Saini N, Liu J, Garaicoehea L. Anti-BCMA nanobodies, nano-chimeric antigen receptors and methods of use thereof. Patent Number: 63/773,622.
2. Neelapu SS, Weng J, Le CC, Liu J, Lee E. Anti-CXCR5 antibodies and chimeric antigen receptors and methods of use thereof. Patent Number: 63/909197.